Biotech | November 26, 2024
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Strengthening focus in Alzheimer's disease and neuroscience pipeline
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Subscribe To Our Newsletter & Stay Updated
